In an era of highly advertised blockbuster medicines, newly approved pharmaceuticals can pose a hazard to the public if not properly monitored following their approval. Drugs are only given to a limited number of healthy individuals during clinical trials, leaving significant questions as to the risks for the population at large. There are limited opportunities for assessment following the product’s introduction onto the market and adverse effects may not be detected. This paper argues that hurdles in tracking long-term safety and effectiveness can be partially remedied through the aggregation and analysis of information collected through pharmaceutical data mining. Pharmaceutical data mining is a process whereby private organizations compile extensive information on patients’ prescription histories, including: the drug prescribed, recommended dosage, and the patient’s subsequent history with the medication. The Canadian government should collect this information and analyze its meaning to better ensure the long-term safety and effectiveness of drugs.
| Identifer | oai:union.ndltd.org:LACETR/oai:collectionscanada.gc.ca:OTU.1807/42848 |
| Date | 22 November 2013 |
| Creators | Goren, Ashley |
| Contributors | Katz, Ariel |
| Source Sets | Library and Archives Canada ETDs Repository / Centre d'archives des thèses électroniques de Bibliothèque et Archives Canada |
| Language | en_ca |
| Detected Language | English |
| Type | Thesis |
Page generated in 0.0019 seconds